Hanall Biopharma (009420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hanall Biopharma (009420) has a cash flow conversion efficiency ratio of 0.047x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.34 Billion ≈ $4.98 Million USD) by net assets (₩157.65 Billion ≈ $106.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Hanall Biopharma to measure how much of total assets are equity-financed.
Hanall Biopharma - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Hanall Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 009420 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Hanall Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanall Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VGI Public Company Limited
BK:VGI-R
|
-0.002x |
|
IDT Corporation
NYSE:IDT
|
0.104x |
|
Fresh Del Monte Produce Inc
NYSE:FDP
|
0.022x |
|
Allied Properties Real Estate Investment Trust
TO:AP-UN
|
0.001x |
|
Amprius Technologies Inc.
NYSE:AMPX
|
-0.341x |
|
PT Bank SMBC Indonesia Tbk
JK:BTPN
|
-0.083x |
|
Inox Wind Energy Limited
NSE:IWEL
|
0.010x |
|
G-III Apparel Group Ltd
NASDAQ:GIII
|
0.129x |
Annual Cash Flow Conversion Efficiency for Hanall Biopharma (2011–2024)
The table below shows the annual cash flow conversion efficiency of Hanall Biopharma from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Hanall Biopharma.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩168.35 Billion ≈ $114.09 Million |
₩9.36 Billion ≈ $6.34 Million |
0.056x | -65.07% |
| 2023-12-31 | ₩186.22 Billion ≈ $126.20 Million |
₩29.64 Billion ≈ $20.09 Million |
0.159x | +6.27% |
| 2022-12-31 | ₩168.26 Billion ≈ $114.03 Million |
₩25.20 Billion ≈ $17.08 Million |
0.150x | +2816.00% |
| 2021-12-31 | ₩163.49 Billion ≈ $110.80 Million |
₩839.87 Million ≈ $569.17K |
0.005x | +0.21% |
| 2020-12-31 | ₩181.27 Billion ≈ $122.85 Million |
₩929.29 Million ≈ $629.77K |
0.005x | -96.49% |
| 2019-12-31 | ₩140.42 Billion ≈ $95.16 Million |
₩20.49 Billion ≈ $13.89 Million |
0.146x | +669.79% |
| 2018-12-31 | ₩116.92 Billion ≈ $79.23 Million |
₩-2.99 Billion ≈ $-2.03 Million |
-0.026x | -106.76% |
| 2017-12-31 | ₩111.20 Billion ≈ $75.36 Million |
₩42.14 Billion ≈ $28.56 Million |
0.379x | +901.08% |
| 2016-12-31 | ₩104.36 Billion ≈ $70.72 Million |
₩3.95 Billion ≈ $2.68 Million |
0.038x | +893.87% |
| 2015-12-31 | ₩95.22 Billion ≈ $64.53 Million |
₩-454.02 Million ≈ $-307.69K |
-0.005x | +93.79% |
| 2014-12-31 | ₩45.81 Billion ≈ $31.04 Million |
₩-3.52 Billion ≈ $-2.38 Million |
-0.077x | +41.14% |
| 2013-12-31 | ₩59.63 Billion ≈ $40.41 Million |
₩-7.78 Billion ≈ $-5.27 Million |
-0.130x | -567.19% |
| 2012-12-31 | ₩78.67 Billion ≈ $53.31 Million |
₩2.20 Billion ≈ $1.49 Million |
0.028x | -80.90% |
| 2011-12-31 | ₩50.70 Billion ≈ $34.36 Million |
₩7.41 Billion ≈ $5.02 Million |
0.146x | -- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more